Rho Granted Extension by NIAID to Study Rate of COVID-19 Infection in US Children
Rho announced its Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, to help determine the rate of the new coronavirus infection in children and their families in the U.S. has been extended through April 2022.
July 30, 2021
by americanpharmaceuticalreview
Cerba Research Wins NIH Contract for Central Lab Services
Cerba Research was awarded a five-year contract for clinical central lab services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
July 29, 2021
by contractpharma
NexImmune Strengthens Management Team with Key Appointments
NexImmune, Inc. (Nasdaq: NEXI) today announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position of Senior Vice President, Translational Science, bringing more than 30 years of experience in translational and clinical research
July 15, 2021
by firstwordpharma
US begins testing mixed COVID-19 vaccine regimens
A Phase I/II trial will enrol 150 individuals already vaccinated against COVID-19 with one vaccine and assess the safety and immunogenicity of a booster dose of a different COVID-19 vaccine.
June 4, 2021
by europeanpharmaceuticalreview
First-in-human universal flu vaccine trial begins
The US National Institutes of Health have begun a first-in-human trial to assess the safety and immunogenicity of a potential universal influenza vaccine candidate, FluMos-v1.
June 3, 2021
by europeanpharmaceuticalreview
Trial to assess anti-CD14 antibody as treatment for hospitalised COVID-19 patients
The trial will evaluate whether the novel IC14 anti-CD14 antibody can reduce recovery time and severity of COVID-19 symptoms in hospitalised patients.
April 15, 2021
by europeanpharmaceuticalreview
NIH begins trial of Moderna’s Covid-19 variant vaccine
The US National Institutes of Health (NIH) has initiated dosing in a new Phase I clinical trial of Moderna’s investigational vaccine candidate, mRNA-1273.351, in adult subjects.
April 2, 2021
by pharmaceutical-technology
NIAID statement on AstraZeneca vaccine and AstraZeneca update
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.
March 24, 2021
by worldpharmanews
NIAID grants $2.5m to 12 institutes for bacteriophage therapy research
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
March 12, 2021
by pharmaceutical-business-review
Sagent Begins NIAID-Sponsored Study Investigating Outpatient COVID-19 Treatments
Sagent Pharmaceuticals announced Camostat mesilate, is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health ...
February 18, 2021
by americanpharmaceuticalreview
Trial to assess AstraZeneca’s long-acting COVID-19 antibody therapy
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
February 10, 2021
by europeanpharmaceuticalreview
Bamlanivimab Reduced Risk of COVID-19 at Nursing Homes in Phase 3 Trial
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company announced.
January 22, 2021
by americanpharmaceuticalreview